Navigation Links
TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
Date:8/31/2008

Landmark ARB trial investigated Micardis(R) (telmisartan) against placebo in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure in ACE inhibitor intolerant high-risk patients receiving current standard of care

RIDGEFIELD, Conn., Aug. 31 /PRNewswire/ -- The primary results of the TRANSCEND(TM)* trial demonstrated that treatment with MICARDIS(R) (telmisartan) 80mg in patients receiving current standard of care resulted in an 8% reduction in the composite endpoint of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure. This reduction was not statistically significant (p=0.216; HR 0.92) compared to patients receiving placebo in addition to current standard of care.(1) Results of the main secondary endpoint of TRANSCEND as pre-specified in the statistical plan demonstrated that telmisartan significantly reduced the risk of cardiovascular death, myocardial infarction and stroke in high-risk cardiovascular patients by 13% compared with those patients already receiving current standard of care (p=0.048).(1) This risk reduction was achieved despite a high proportion of patients receiving proven therapies such as statins, anti-platelet agents or beta blockers. The main secondary endpoint of TRANSCEND mirrors the primary endpoint of the landmark HOPE trial.(2) A post-hoc analysis to adjust for multiplicity and overlap with primary endpoint showed a p-value of 0.068.(1) The results were presented today at the annual meeting of the European Society of Cardiology in Munich, Germany and published online in The Lancet.

In high-risk patients who cannot tolerate an angiotensin-converting enzyme (ACE) inhibitor, the TRANSCEND trial was designed to investigate potential cardiovascular risk reduction benefits using the second-generation angiotensin II receptor blocker (ARB) telmisartan. Telmisartan was compared to placebo on top of
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... 2013 Life Science Firm of the Year by the Tech ... honored at the TCM,s 25 th Annual Tech Awards ... Tech Awards Celebration recognizes the leaders and innovators in the ... and the surrounding regions. "We are ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... , May 23, 2013 Neurocrine Biosciences, Inc. (Nasdaq: ... Gorman , President and Chief Executive Officer of Neurocrine ... Annual dbAccess Health Care Conference in Boston.   ... at 11:20 a.m. Eastern Time / 8:20 a.m. Pacific Time.  ... the Company,s website at http://www.neurocrine.com . ...
Breaking Medicine Technology:Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 2 "A two-year,survival rate of more ... anaplastic,astrocytoma suggests a breakthrough in this devastating ... Neuro-Oncologist and Coordinating,Investigator of the Phase IIb ... or refractory high-grade glioma, while presenting the,data ...
... American Transplant Congress in Toronto, MIAMI, June ... in,the Departments of Surgery and Pathology at the ... have corroborated the value of,monitoring cell- mediated immunity ... a regular laboratory assay of cell function,(ImmuKnow(R)/Cylex). Their ...
Cached Medicine Technology:Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 2Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 3Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements 4University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 2University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 3University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients 4
(Date:5/23/2013)... 2013 Vegas Hotel Escapes, the ... announce all new vacation packages for the upcoming ... Las Vegas for this patriotic holiday will be ... to VegasHotelEscapes.com's new special pricing available on VegasHotelEscapes.com's ... it guarantees the lowest prices possible on vacation ...
(Date:5/23/2013)... New Jersey (PRWEB) May 23, 2013 ... Americans suffering from irritable bowel syndrome (IBS), the food ... on your holiday fun. , “While hot dogs and ... plate during the warm weather months, IBS sufferers often ... says Deborah Sokol, MD, a gastroenterologist with Lourdes Medical ...
(Date:5/23/2013)... 23, 2013 Onlinefitnessreview.com recently published a ... to determine what makes this diet work and how ... highlights three main components of the program: eliminating foods ... mindset and the personal motivation that is needed to ... days to keep the metabolism rate in top gear. ...
(Date:5/23/2013)... Mann HealthDay Reporter , , THURSDAY, May 23 ... take to help treat hip and knee osteoarthritis may ... for developing glaucoma, a small new study of older ... an increase of intraocular pressure (IOP) or pressure inside ... leading causes of blindness. In the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Memorial Day ... , Chaplains have been a part of the U.S. ... Day, like those preceding it, these men and women ... the United States of America. As veterans transition ... their migration to the workplace chaplaincy world. , ...
Breaking Medicine News(10 mins):Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 2Health News:Memorial Day Focus Spotlight on Military Chaplains Transitioning in the Marketplace 3
... affect psychological well-being, , FRIDAY, Sept. 25 (HealthDay News) -- ... lose IQ points. , The good news is that it ... at least one expert believes that part of the reason ... in the United States and elsewhere. , That,s the view ...
... Life ... with one of its Northwest Division President,s Awards on Monday, Sept. 21. , ... Kirkland, WA (PRWEB) September 25, 2009 -- ... Care Center of Kirkland , with one of its Northwest Division President,s Awards on Monday, ...
... ... portable oxygen machine from Invacare with an amazing 1.8 liters per minute ... oxygen output. Now, oxygen therapy patients requiring large doses of oxygen can ... mobility and freedom. This new portable concentrator is now available for online ...
... researchers say , THURSDAY, Sept. 24 (HealthDay News) -- ... with carpal tunnel syndrome who don,t have severe nerve ... included 44 patients who had surgery and 52 patients ... ultrasound. A year after treatment, the patients, hand function ...
... CA SEPTEMER 24, 2009 Results from a ... combination of giving patients clopidogrel, a blood thinner commonly ... such as omeprazole, known as proton pump inhibitors (PPIs), ... studies had suggested. The results were presented at the ...
... BEDFORD, Mass., Sept. 24 ... HOLX ), a leading developer, manufacturer and supplier ... dedicated to serving the healthcare needs of women, today ... Clinical Excellence (NICE), in its updated guidance for hysteroscopic ...
Cached Medicine News:Health News:Spanking May Lower Kids' IQs 2Health News:Spanking May Lower Kids' IQs 3Health News:Local Nursing Home Leader Receives Life Care's Northwest Division President's Award 2Health News:New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 2Health News:New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 3Health News:New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 4Health News:New Invacare SOLO2 Portable Oxygen Concentrator Available At Vitality Medical 5Health News:Surgery Best for Carpal Tunnel Syndrome 2Health News:Surgery Best for Carpal Tunnel Syndrome 3Health News:Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine 2Health News:New U.K. NICE Guidance Supports Use of Hologic's Adiana(R) Permanent Contraception System 2Health News:New U.K. NICE Guidance Supports Use of Hologic's Adiana(R) Permanent Contraception System 3Health News:New U.K. NICE Guidance Supports Use of Hologic's Adiana(R) Permanent Contraception System 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: